Price
Target price
€3.79
€3.79
-1.570%
-0.06
-1.570%
-
03.12.25 / Tradegate
WKN: A14QR9 / Name: Cerenis / Stock / Biotechnology & Medical Research / Micro Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Cerenis Therapeutics Holding S.A. Stock
A loss of -1.570% shows a downward development for Cerenis Therapeutics Holding S.A..
For the coming years our community has positive and negative things to say abot the Cerenis Therapeutics Holding S.A. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Cerenis Therapeutics Holding S.A. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
S********** s********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cerenis Therapeutics Holding S.A. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cerenis Therapeutics Holding S.A. | -1.570% | -7.457% | -2.323% | - | - | - | - |
| Genoway S.A. Inh. | -1.580% | 1.220% | -4.231% | -32.703% | -31.215% | -38.060% | -15.878% |
| Sensorion SA | -5.460% | -6.734% | -13.438% | -58.283% | -53.679% | -24.626% | -81.284% |
| Hybrigenics S.A. | 3.850% | -3.571% | -6.897% | -26.027% | -15.625% | -91.818% | -97.340% |
News
ABIONYX Pharma and SEBIA Announce an Exclusive Global Strategic Partnership to Transform Sepsis Diagnosis
Regulatory News:
ABIONYX Pharma, (FR0012616852 – ABNX – eligible PEA PME), a next-generation biopharma company pioneering a new therapeutic era in sepsis and critical care through its
ABIONYX Pharma Enters Advanced Strategic Discussions with IHU SEPSIS, the World’s First Center Dedicated to Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX), a next-generation biotechnology company developing breakthrough therapies for severe and underserved diseases, today announced it has entered advanced
ABIONYX Pharma Announces Landmark Validation: A Study Published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the world's only recombinant apoA-I, today announced the publication of a ground breaking